Marzan(and Minions):
Here are some predictions:
1. There will be no PR of any sort prior to or after ASCO for the short to intermediate term;
2. There will, almost assuredly, be a "sort" of update on the SAPs. LP will state that they are nearing completion and will be submitted "soon" to the relevant RAs. She will not venture a guess on when these submissions will be approved because this is out of her control. Stay tuned.
3. Wrt to collection of data and resolution of inquiries, she will only state that this is a ginormous task but we are getting there. Stay tuned.
4. There will be no guideline on when top line will be announced. " We are pedal to the metal however as stated previously, there are areas out of our control. We understand investor frustrations but patience is important. As soon as we can, top line will be revealed. Stay tuned."
5. Number of patients currently alive will not be revealed. All part of top line announcement.
6. Vague information on the combo trials and partners. "We are focusing on getting to DC VAX L top line."'
7. No other information of any significance. Pretty much the same as the Rago update, with no new information. That is why the stock got slapped today. Nothing really new. Essentially, MB will provide a regurgitation and that they are excitedly awaiting unblinding. Pretty much in Rago's footsteps. Stay tuned.
Monday, June 3, the stock gets punished and will hit the mid to lower twenty cent range. As the summer wears on, with no news, the stock will hit new lows, probably mid-teens. Even with impressive top line, it won't be unequivocal or irrefutable at least in some respects. I don't expect the stock price to achieve even one dollar upon top line announcement. Much less if at all, if top line is not unequivocally impressive.
Unfortunately, if ASCO comes and goes with nothing of real significance, it is another wasted opportunity and further testament to LP/LG strategy of silence, equivocation and obfuscation. ASCO is an opportunity to change the pattern. Surely, there must be something of note that can be revealed at ASCO to mitigate assault on the stock price. If it hits new lows, much of top line news, if good, will be spent on recovering current levels. Surely, NWBO management understands this. Fingers crossed and stay tuned.
